RAMELTEON

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C16H21NO2
Molecular Weight	259.3434
Optical Activity	( - )
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCC(=O)NCC[C@@H]1CCC2=C1C3=C(OCC3)C=C2

InChI

InChIKey=YLXDSYKOBKBWJQ-LBPRGKRZSA-N

InChI=1S/C16H21NO2/c1-2-15(18)17-9-7-12-4-3-11-5-6-14-13(16(11)12)8-10-19-14/h5-6,12H,2-4,7-10H2,1H3,(H,17,18)/t12-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C16H21NO2
Molecular Weight	259.3434
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.takeda.com/news/2011/20111007_3902.html

Ramelteon was approved by the United States (U.S.) in July 2005, and the Japanese Ministry of Health, Labour and Welfare in April 2010. It is currently available in the USA and Japan as ROZEREM and is indicated for the treatment of insomnia characterized by difficulty with sleep onset. In October 7, 2011, Takeda has decided to discontinue the development of ramelteon in Europe for the treatment of insomnia in order to best optimize Takeda’s resources for its research and development activities. Ramelteon is a melatonin receptor agonist with both high affinity for melatonin MT1 and MT2 receptors and selectivity over the MT3 receptor. Ramelteon demonstrates full agonist activity in vitro in cells expressing human MT1 or MT2 receptors, and high selectivity for human MT1 and MT2 receptors compared to the MT3 receptor. The activity of ramelteon at the MT1 and MT2 receptors is believed to contribute to its sleep-promoting properties since these receptors are acted upon by endogenous melatonin and are thought to be involved in the maintenance of the circadian rhythm underlying normal sleep-wake cycles. Ramelteon has no appreciable affinity for the GABA receptor complex or for receptors that bind neuropeptides, cytokines, serotonin, dopamine, noradrenaline, acetylcholine, and opiates.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Melatonin receptor 1 Target ID: CHEMBL2094268 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15494157	Agonist 2752

Conditions

Condition	Modality	Targets	Highest Phase	Product
Insomnia 111 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf	Primary		Approved 8583	ROZEREM Approved Use ROZEREM is indicated for the treatment of insomnia characterized by difficulty with sleep onset. The clinical trials performed in support of efficacy were up to 6 months in duration. The final formal assessments of sleep latency were performed after 2 days of treatment during the crossover study (elderly only), at 5 weeks in the 6-week studies (adults and elderly), and at the end of the 6-month study (adults and elderly) [see Clinical Studies (14) Launch Date 2005

C_max

Value	Dose	Co-administered	Analyte	Population
25.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16432265	64 mg single, oral dose: 64 mg route of administration: Oral experiment type: SINGLE co-administered:		RAMELTEON serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
36.1 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16432265	64 mg single, oral dose: 64 mg route of administration: Oral experiment type: SINGLE co-administered:		RAMELTEON serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16432265	64 mg single, oral dose: 64 mg route of administration: Oral experiment type: SINGLE co-administered:		RAMELTEON serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
30% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16432265	64 mg single, oral dose: 64 mg route of administration: Oral experiment type: SINGLE co-administered:		RAMELTEON serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Doses

Dose	Population	Adverse events
32 mg 1 times / day multiple, oral Highest studied dose Dose: 32 mg, 1 times / day Route: oral Route: multiple Dose: 32 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21955196	unhealthy, 42.8 years Health Status: unhealthy Age Group: 42.8 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/21955196	Other AEs: Somnolence, Malaise... Other AEs: Somnolence (12.7%) Malaise (1.6%) Dizziness (3.2%) Nasopharyngitis (4.8%) Sources: https://pubmed.ncbi.nlm.nih.gov/21955196
40 mg 1 times / day multiple, oral Overdose Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/22926624	unhealthy, 47 years Health Status: unhealthy Age Group: 47 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/22926624	Sources: https://pubmed.ncbi.nlm.nih.gov/22926624
8 mg 1 times / day steady, oral Recommended Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf	Disc. AE: Somnolence, Dizziness... AEs leading to discontinuation/dose reduction: Somnolence (0.8%) Dizziness (0.5%) Nausea (0.3%) Fatigue (0.3%) Headache (0.3%) Insomnia (0.3%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf
160 mg single, oral Highest studied dose Dose: 160 mg Route: oral Route: single Dose: 160 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf	unknown Health Status: unknown Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf

AEs

AE	Significance	Dose	Population
Malaise	1.6%	32 mg 1 times / day multiple, oral Highest studied dose Dose: 32 mg, 1 times / day Route: oral Route: multiple Dose: 32 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21955196	unhealthy, 42.8 years Health Status: unhealthy Age Group: 42.8 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/21955196
Somnolence	12.7%	32 mg 1 times / day multiple, oral Highest studied dose Dose: 32 mg, 1 times / day Route: oral Route: multiple Dose: 32 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21955196	unhealthy, 42.8 years Health Status: unhealthy Age Group: 42.8 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/21955196
Dizziness	3.2%	32 mg 1 times / day multiple, oral Highest studied dose Dose: 32 mg, 1 times / day Route: oral Route: multiple Dose: 32 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21955196	unhealthy, 42.8 years Health Status: unhealthy Age Group: 42.8 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/21955196
Nasopharyngitis	4.8%	32 mg 1 times / day multiple, oral Highest studied dose Dose: 32 mg, 1 times / day Route: oral Route: multiple Dose: 32 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21955196	unhealthy, 42.8 years Health Status: unhealthy Age Group: 42.8 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/21955196
Fatigue	0.3% Disc. AE	8 mg 1 times / day steady, oral Recommended Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf
Headache	0.3% Disc. AE	8 mg 1 times / day steady, oral Recommended Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf
Insomnia	0.3% Disc. AE	8 mg 1 times / day steady, oral Recommended Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf
Nausea	0.3% Disc. AE	8 mg 1 times / day steady, oral Recommended Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf
Dizziness	0.5% Disc. AE	8 mg 1 times / day steady, oral Recommended Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf
Somnolence	0.8% Disc. AE	8 mg 1 times / day steady, oral Recommended Dose: 8 mg, 1 times / day Route: oral Route: steady Dose: 8 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021782lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946 inhibitor 2252 inducer 1087	substrate 1193 inducer 440	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2C19 2057 P-gp 1741	CYP1A2 1197 CYP2C 16 P-gp 2052	CYP1A2 832

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP1A2 2333	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_biopharmr.pdf Page: 11, 28	no
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_biopharmr.pdf Page: 11.0	no
CYP2C9 2497	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_biopharmr.pdf Page: 11.0	no
CYP3A4 2633	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_biopharmr.pdf Page: 11.0	no
CYP3A4 2633	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_biopharmr.pdf Page: 11.0	no
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_biopharmr.pdf Page: 11, 13	no	no (co-administration study) Comment: theophylline AUC increased 40% and Cmax increased 35% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_biopharmr.pdf Page: 11, 13
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_biopharmr.pdf Page: 11, 13	no	no (co-administration study) Comment: dextromethorphan AUC and Cmax did not change Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_biopharmr.pdf Page: 11, 13
P-gp 1932	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_biopharmr.pdf Page: 11, 60, 63	no	no (co-administration study) Comment: ramelteon decreased digoxin exposure by 3% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_biopharmr.pdf Page: 11, 60, 63

Drug as victim

Target	Modality	Activity	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_biopharmr.pdf Page: 60.0	inconclusive
CYP1A2 1197	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_biopharmr.pdf Page: 11, 13	major	yes (co-administration study) Comment: fluvoxamine increased ramelteon AUC 190-fold and Cmax 70-fold; rifampin decreased total expsoure to ramelteon by 80% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_biopharmr.pdf Page: 11, 13
CYP2C 16	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_biopharmr.pdf Page: 11, 13	minor	yes (co-administration study) Comment: rifampin decreased total expsoure to ramelteon by 80% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_biopharmr.pdf Page: 11, 13
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_biopharmr.pdf Page: 11, 13	minor	yes (co-administration study) Comment: ketaconazole increased ramelteon AUC by 84% and Cmax 36%; rifampin decreased total expsoure to ramelteon by 80% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_biopharmr.pdf Page: 11, 13
CYP2C9 1193	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_biopharmr.pdf Page: 13.0	yes	yes (co-administration study) Comment: fluconazole increased AUC by 150% and Cmax by 150%; rifampin decreased total expsoure to ramelteon by 80% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_biopharmr.pdf Page: 13.0

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021782s000_Rozerem_pharmr_CORRECTED_REVIEW.pdf Page: 53, 66

Sourcing

Vendor/Aggregator	ID	URL
AA Blocks	AA0038TN	http://www.aablocks.com/goods/Goods/detail?id=AA0038TN
Aaron Chemicals	AR0039LF	http://www.aaronchem.com/196597-26-9
abcr GmbH	AB452183	http://www.abcr.com/shop/en/AB452183
AbMole Bioscience	M5919	http://www.abmole.com/products/ramelteon.html
Achemo Scientific Limited	AC-63628	http://www.achemo.com/search/?Keyword= 196597-26-9
Achemtek	0102-022116	http://www.achemtek.com/196597-26-9
Acorn PharmaTech	ACN-054096	http://www.acornpharmatech.com/
Active Biopharma	ABP001059	http://www.activebiopharma.com/196597-26-9
Adooq BioScience	A10777	https://www.adooq.com/ramelteon-tak-375.html
AEchem Scientific Corp., USA	AE1-002187	http://www.aechemsc.com/info_products/AE1-002187.php
AK Scientific, Inc. (AKSCI)	Q499	http://www.aksci.com/item_detail.php?cat=Q499
Alfa Chemistry	AP196597269-A	https://reagents.alfa-chemistry.com/product/ramelteon-solution-cas-196597-26-9-7285.html
Alfa Chemistry	AP196597269-B	https://reagents.alfa-chemistry.com/product/ramelteon-cas-196597-26-9-7286.html
Allbio Pharm Co., Ltd	AF09776	http://www.allbiopharm.com/product/n/AF09776
Ambeed	A428570	https://www.ambeed.com/products/196597-26-9.html
Angene	AGN-PC-0QOEYH	http://www.angenechemical.com/productshow/AGN-PC-0QOEYH.html
ApexBio Technology	A1748	http://www.apexbt.com/ramelteon.html
Aurora Fine Chemicals LLC	A17.921.663	http://online.aurorafinechemicals.com/info?ID=A17.921.663
Aurum Pharmatech LLC	Q-4378	http://www.Aurumpharmatech.com/Product/ProductDetails/Q_4378
AvaChem Scientific	2570	http://www.avachem.com/productSearch.asp?2570
BioCrick	BCC1107	http://www.biocrick.com/Ramelteon-BCC1107.html
BioSynth	J-502508	https://www.biosynth.com/en/products/all-products/products/J-502508.html
BLD Pharm	BD150225	http://www.bldpharm.com/products/196597-26-9.html
Boerchem	BC225579	http://www.boerchem.com/?product_38007.html
Capot Chemical	19120	http://www.capotchem.com/en/19120.htm
Capot Chemical	PubChem19120	http://www.capotchem.com/en/19120.htm
Chem Scene	CS-0382	http://www.chemscene.com/196597-26-9.html
Chemenu	CM110503	http://www.chemenu.com/products/CM110503
ChemFaces	CFN90021	http://www.chemfaces.com/natural/Ramelteon-CFN90021.html
ChemMol	2100070	http://www.chemmol.com/chemmol/2100070.html
ChemMol	30111175	http://www.chemmol.com/chemmol/30111175.html
ChemMol	44007511	http://www.chemmol.com/chemmol/44007511.html
ChemMol	49400038	http://www.chemmol.com/chemmol/49400038.html
Chemspace	CSSB00020625256	https://chem-space.com/CSSB00020625256
Chiralblock Biosciences	CB10282	http://www.chiralblock.com/products/196597-26-9.html
Combi-Blocks	QJ-0181	http://www.combi-blocks.com/cgi-bin/find.cgi?QJ-0181
CSNpharm	CSN11830	https://www.csnpharm.com/products/ramelteon.html
DC Chemicals	DC7828	http://www.dcchemicals.com/product_show-Ramelteon.html
Enamine	Z2037281108	https://www.enaminestore.com/catalog/Z2037281108
eNovation Chemicals	D521759	http://www.enovationchem.com/productDetails.asp?productID=D521759
Glentham Life Sciences	GP4371	http://www.glentham.com/products/product/GP4371/
Hairui	HR133856	http://www.hairuichem.com/en/product/196597-26-9.html
iChemical	EBD14983	http://www.ichemical.com/products/196597-26-9.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
Lab Network	LN01312113	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01312113
LGC Standards	LGCAMP3666.00-11	https://www.lgcstandards.com/US/en/p/LGCAMP3666.00-11
LGC Standards	MM3666.00	https://www.lgcstandards.com/US/en/p/MM3666.00
Matrix Scientific	125309	https://www.matrixscientific.com/125309.html
MedChem Express	HY-A0014	https://www.medchemexpress.com/ramelteon.html
MuseChem	A001192	https://www.musechem.com/product/A001192.html
OChem	25538	http://www.ocheminc.com/index.php?act=psearch&pid=597R269
Parchem	18232	http://www.parchem.com/chemical-supplier-distributor/Ramelteon-008232.aspx
Renno Tech	RL02472	http://www.rennotech.com/product_show.asp?id=2721
Selleck Chemicals	S1259	http://www.selleckchem.com/products/Ramelteon.html
Sigma-Aldrich	R-016_CERILLIAN	https://www.sigmaaldrich.com/catalog/product/cerillian/r016?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule	S541036	http://www.smolecule.com/products/s541036
Synblock Inc	PB27872	http://www.synblock.com/product/196597-26-9.html
THE BioTek	bt-279735	https://www.thebiotek.com/product/inhibitors/bt-279735
Tocris	6777	https://www.tocris.com/products/tak-375_6777
TripleBond	CR0011	http://www.triplebond-canada.com/prod/1552/
Yuhao Chemical	LL2545	http://www.chemyuhao.com/196597-26-9.html

PubMed

Title	Date	PubMed
Gateways to clinical trials.	2004 Dec	15672123
Gateways to clinical trials.	2004 Nov	15632957
The sleep-promoting action of ramelteon (TAK-375) in freely moving cats.	2004 Nov 1	15586784
Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds.	2005	16336040
Sleep and aging: prevalence of disturbed sleep and treatment considerations in older adults.	2005	16336039
Ramelteon.	2005	16332146
Melatonin and sleep in aging population.	2005 Dec	16183237
Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment.	2005 Mar	16173650
Fresh from the pipeline: Ramelteon.	2005 Nov	16299918
Ramelteon (Rozerem) for insomnia.	2005 Nov 7	16267494
Gateways to clinical trials.	2005 Oct	16273137
Use of sleep-promoting medications in nursing home residents : risks versus benefits.	2006	16732687
Practical considerations of new drugs: new choices for old problems.	2006 Apr	16669748
Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia.	2006 Feb	16432265
An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia.	2006 Jan	16309958
Effect of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist, on motor performance in mice.	2006 Jul 24	16730121
Acute and chronic effects of ramelteon in rhesus monkeys (Macaca mulatta): dependence liability studies.	2006 Jun	16768605
A new sleeping pill.	2006 Oct	17186577
Ramelteon for the treatment of insomnia.	2006 Oct	17157111
Eszopiclone for late-life insomnia.	2007	18044182
Role of the melatonin system in the control of sleep: therapeutic implications.	2007	18020480
Update on the safety considerations in the management of insomnia with hypnotics: incorporating modified-release formulations into primary care.	2007	17599165
Use of non-benzodiazepine hypnotics in the elderly: are all agents the same?	2007	17447827
Drug Insight: the use of melatonergic agonists for the treatment of insomnia-focus on ramelteon.	2007 Apr	17410109
Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2.	2007 Apr	17389558
Putting "sleepdriving" and new safety warning in perspective.	2007 Aug	17712908
Treatment options for insomnia.	2007 Aug 15	17853625
Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia.	2007 Aug 15	17803013
Greater incidence of depression with hypnotic use than with placebo.	2007 Aug 21	17711589
[Recent and potential drugs for treatment of insomnia].	2007 Jan	17220574
Therapeutic options for sleep-maintenance and sleep-onset insomnia.	2007 Jan	17192164
New perspectives for the treatment of disorders of sleep and arousal.	2007 Jul	17652996
Hypnotic sedative drugs.	2007 Jun	17849930
The management of insomnia in the older adult.	2007 Jun	17633595
A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia.	2007 May	17519067
Gateways to clinical trials.	2007 Oct	18040531
Design and synthesis of new N1 and C3-substituted 4-fluoroindolic melatoninergics.	2007 Oct	17986002
Self-reported efficacy and tolerability of ramelteon 8 mg in older adults experiencing severe sleep-onset difficulty.	2007 Sep	17996657
Safety of ramelteon in individuals with mild to moderate obstructive sleep apnea.	2007 Sep	17294232
Effect of ramelteon, a selective MT(1)/MT (2)-receptor agonist, on respiration during sleep in mild to moderate COPD.	2008 Aug	18060441
Pharmacotherapy for insomnia.	2008 Feb	18035234
[Drugs for insomnia and improving quality of life (QOL): research and development of ramelteon, an MT1/MT2-receptor agonist].	2008 Jan	18187878
Ramelteon: a melatonin receptor agonist for the treatment of insomnia.	2008 Jan-Mar	18296808
Melatonin and its agonists: an update.	2008 Oct	18827285
Circadian phase-shifting effects of repeated ramelteon administration in healthy adults.	2008 Oct 15	18853704
Possibility that certain hypnotics might cause cancer in skin.	2008 Sep	18844818
Hypnotics and skin cancer: hint at drug carcinogenesis, coincidence, or benefit of more sleep?	2008 Sep	18844817
Sleep dysfunction in heart failure.	2008 Sep	18782505
Ramelteon: a novel approach in the treatment of insomnia.	2008 Sep	18648020
The effects of ramelteon in a first-night model of transient insomnia.	2009 Jan	18691937

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dose 8 mg taken within 30 minutes of going to bed. It is recommended that drug not be taken with or immediately after a high fat meal.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:16:13 GMT 2025` Edited by `admin` on `Mon Mar 31 18:16:13 GMT 2025`
Record UNII	901AS54I69
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ROZEREM

Preferred Name

English

RAMELTEON

Official Name

English

RAMELTEON [JAN]

Common Name

English

RAMELTEON [VANDF]

Common Name

English

TAK375

Code

English

(-)-N-(2-(((8S)-1,6,7,8-TETRAHYDRO-2H-INDENO(5,4-.BETA.)FURAN-8-YL)ETHYL)PROPANAMIDE

Common Name

English

RAMELTEON [HSDB]

Common Name

English

RAMELTEON [MART.]

Common Name

English

RAMELTEON [ORANGE BOOK]

Common Name

English

RAMELTEON [USAN]

Common Name

English

TAK-375

Code

English

Ramelteon [WHO-DD]

Common Name

English

RAMELTEON [MI]

Common Name

English

PROPANAMIDE, N-(2-((8S)-1,6,7,8-TETRAHYDRO-2H-INDENO(5,4-.BETA.)FURAN-8-YL)ETHYL)-

Common Name

English

ramelteon [INN]

Common Name

English

Classification Tree Code System Code

WHO-ATC

N05CH02